vadimezan has been researched along with Sensitivity and Specificity in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlin, S; Ling, CC; Lorenzen, S; O'Donoghue, JA; Oehler, C; Russell, J; Zanzonico, P | 1 |
| Li, W; Lin, H; Smith, HT; Tse, FL | 1 |
| Baguley, BC; Feng, X; Kestell, P; Paxton, JW; Zhou, S | 1 |
| He, P; Rudek, MA; Vogelstein, B; Zhang, X; Zhao, M | 1 |
| Kestell, P; McCall, J; Paxton, JW; Tingle, MD; Zhou, S | 1 |
| Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 2 |
| Chiang, D; Chin, R; Kestell, P; Paxton, JW; Zho, S | 1 |
8 other study(ies) available for vadimezan and Sensitivity and Specificity
| Article | Year |
|---|---|
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; HT29 Cells; Humans; Mice; Mice, Nude; Misonidazole; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xanthones | 2011 |
Developing a robust ultrafiltration-LC-MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma.
Topics: Chromatography, Liquid; Drug Stability; Humans; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Ultrafiltration; Xanthones | 2011 |
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Topics: Antineoplastic Agents; Caco-2 Cells; Chromatography, High Pressure Liquid; Glucuronides; Humans; Sensitivity and Specificity; Spectrometry, Fluorescence; Xanthones | 2004 |
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma.
Topics: Animals; Antineoplastic Agents; Calibration; Chromatography, Liquid; Humans; Mice; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Xanthones | 2007 |
Determinaton of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hydroxides; Microsomes, Liver; NADP; Oxidation-Reduction; Phosphoric Acids; Potassium Compounds; Quality Control; Sensitivity and Specificity; Uridine Diphosphate Glucuronic Acid; Xanthenes; Xanthones | 1999 |
Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Reproducibility of Results; Sensitivity and Specificity; Serum Albumin; Xanthenes; Xanthones | 2001 |
Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Ultrafiltration; Xanthenes; Xanthones | 2001 |
High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Microsomes, Liver; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Xanthenes; Xanthones | 2002 |